Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06189963). This is a study registration, not published results. Lead sponsor: NKGen Biotech, Inc.. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 36 participants (ESTIMATED). Conditions: Moderate Alzheimer Disease. Interventions: BIOLOGICAL: SNK01; OTHER: Placebo. Primary outcome measures: Number of participants with dose-limiting toxicity , 3 weeks; Maximum tolerated dose determination , 3 weeks; Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 , 1 Year; Preliminary efficacy in cognitive assessment scores of CDR-SB , 1 Year; Preliminary efficacy in cognitive assessment scores of MMSE , 1 Year; Preliminary efficacy in cognitive assessment scores of NPI , 1 Year; Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe , 1 Year; Preliminary efficacy in cognitive assessment scores of ADAS-Cog , 1 Year. Brief summary: The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers